Zoetis Inc.: A Global Leader in Animal Health

Zoetis Inc. is a prominent figure in the global animal health industry, known for its comprehensive approach to the discovery, development, manufacture, and commercialization of veterinary vaccines and medicines. Headquartered in Parsippany, New Jersey, USA, Zoetis operates in more than 100 countries, providing a wide array of products and services to veterinarians and livestock farmers globally.

Location and Facilities

With a strong global footprint, Zoetis has strategically positioned its manufacturing, research, and commercial operations worldwide. The company's primary research facilities are located in the United States, complemented by significant international offices and production sites in countries such as Belgium and Brazil. A notable facility is located in Kalamazoo, Michigan, where Zoetis produces Dectomax-CA1, an essential product for livestock health.

Financial Indicators

In 2022, Zoetis reported robust financial results with revenues reaching approximately $8.1 billion. The company's financial health is reflected in its market capitalization of around $80 billion, underscoring its strong market presence and investor confidence.

Important Company Events

A recent significant milestone for Zoetis is the conditional approval from the U.S. Department of Agriculture (USDA) for its avian influenza vaccine. This vaccine is designed to protect poultry from the avian flu virus, addressing a critical concern for poultry farmers and agricultural stability. This development underscores Zoetis' commitment to innovation in animal health and addressing emerging diseases.

Company Plans

Looking forward, Zoetis aims to expand its product offerings and strengthen its position in the veterinary vaccine market. The company is heavily investing in research and development to discover innovative solutions that tackle global challenges in animal health. This includes expanding their vaccine portfolio to combat various diseases affecting livestock.

Zoetis is also advancing in genetic partnerships, demonstrated by its collaboration with McCarty Family Farms and UNIFORM-Agri. Through these partnerships, Zoetis enhances decision-making for dairy producers using genetic insights and herd management software, highlighting its dedication to advancing the dairy industry. Additionally, Zoetis sponsors Dectomax CA-1, a drug authorized for use in various types of dairy cattle, including lactating and dry cows, as well as replacement heifers aged 20 months and older.

Furthermore, Zoetis sponsors a manual and associated pocket guide to support on-farm resource development for U.S. dairy farmers, reflecting its ongoing commitment to the agricultural community.

Modified: 2026/06/17

---